Myriad/Crescendo's rheumatoid arthritis test shows viability in new trial

Myriad Genetics ($MYGN) paid $270 million for Crescendo Bioscience in February and isn't wasting any time promoting the accomplishments of its now wholly owned subsidiary. According to the company, a new study affirms the clinical viability of Crescendo's Vectra DA, a protein-based test designed to assess a patient's rheumatoid arthritis disease progression and activity. The trial took place in Sweden involving 235 patients with early-stage rheumatoid arthritis who hadn't taken a prescribed treatment yet. Myriad/Crescendo said the data shows the test's usefulness as helping to determine more personalized treatments. Details are published online in the journal Annals of the Rheumatic Diseases. Release | Abstract

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.